Currently viewing the tag: "Inter Partes Review"

On July 20, 2018, the Federal Circuit decided the matter of Saint Regis Mohawk Tribe and Allergan v. Mylan Pharmaceuticals Inc., where the petitioners (Allergan) attempted to terminate an inter partes review (IPR) challenge in the USPTO by asserting tribal sovereign immunity. In St. Regis, Allergan, a pharmaceutical company, moved to dismiss Mylan’s IPR challenge […]

Continue Reading

In November, the Supreme Court will hear argument on whether Inter Partes Reviews (IPRs), one of the most influential changes of the American Invents Act, are an unconstitutional taking of property.  IPRs are a post-issuance review of patent validity before the Patent Trial and Appeal Board (PTAB). This administrative trial before a panel of […]

Continue Reading